Regenxbio IncNASDAQ:RGNX
- LAST PRICE13.5800
- TODAY'S CHANGE (%)-0.1300 (-0.9482%)
- Bid / Lots13.5000/ 1
- Ask / Lots14.5300/ 1
- Open / Previous Close13.5600 / 13.7100
- Day Range
- 52 Week Range
- Volume454,020
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RGNX |
|---|---|---|
| 09:32 ET | 3430 | 13.56 |
| 09:36 ET | 100 | 13.59 |
| 09:38 ET | 100 | 13.66 |
| 09:41 ET | 1000 | 13.84 |
| 09:43 ET | 600 | 13.88 |
| 09:45 ET | 1152 | 13.87 |
| 09:48 ET | 100 | 13.885 |
| 09:50 ET | 800 | 13.875 |
| 09:52 ET | 4328 | 13.975 |
| 09:54 ET | 1011 | 13.86 |
| 09:56 ET | 300 | 13.81 |
| 09:57 ET | 3022 | 13.75 |
| 09:59 ET | 348 | 13.84 |
| 10:01 ET | 200 | 13.82 |
| 10:03 ET | 2700 | 13.84 |
| 10:08 ET | 100 | 13.83 |
| 10:10 ET | 100 | 13.85 |
| 10:12 ET | 500 | 13.9 |
| 10:14 ET | 302 | 13.83 |
| 10:15 ET | 300 | 13.82 |
| 10:17 ET | 1000 | 13.78 |
| 10:21 ET | 4298 | 13.75 |
| 10:24 ET | 495 | 13.69 |
| 10:26 ET | 500 | 13.695 |
| 10:28 ET | 958 | 13.72 |
| 10:30 ET | 1800 | 13.67 |
| 10:32 ET | 719 | 13.698 |
| 10:33 ET | 300 | 13.69 |
| 10:37 ET | 3273 | 13.71 |
| 10:39 ET | 300 | 13.73 |
| 10:42 ET | 350 | 13.76 |
| 10:44 ET | 100 | 13.73 |
| 10:46 ET | 100 | 13.695 |
| 10:51 ET | 101 | 13.6601 |
| 10:53 ET | 442 | 13.655 |
| 10:55 ET | 321 | 13.62 |
| 10:57 ET | 7063 | 13.55 |
| 11:02 ET | 100 | 13.6 |
| 11:08 ET | 5177 | 13.59 |
| 11:09 ET | 200 | 13.55 |
| 11:11 ET | 100 | 13.54 |
| 11:13 ET | 218 | 13.545 |
| 11:15 ET | 100 | 13.57 |
| 11:18 ET | 410 | 13.605 |
| 11:24 ET | 698 | 13.6 |
| 11:26 ET | 255 | 13.6299 |
| 11:29 ET | 512 | 13.665 |
| 11:31 ET | 219 | 13.67 |
| 11:33 ET | 1350 | 13.59 |
| 11:42 ET | 1826 | 13.59 |
| 11:44 ET | 255 | 13.585 |
| 11:45 ET | 100 | 13.58 |
| 11:49 ET | 110 | 13.585 |
| 11:56 ET | 100 | 13.61 |
| 11:58 ET | 200 | 13.64 |
| 12:05 ET | 100 | 13.645 |
| 12:07 ET | 574 | 13.652 |
| 12:09 ET | 116 | 13.645 |
| 12:14 ET | 1250 | 13.68 |
| 12:16 ET | 421 | 13.65 |
| 12:20 ET | 200 | 13.655 |
| 12:23 ET | 814 | 13.635 |
| 12:25 ET | 455 | 13.63 |
| 12:27 ET | 700 | 13.61 |
| 12:32 ET | 231 | 13.595 |
| 12:38 ET | 598 | 13.625 |
| 12:43 ET | 154 | 13.63 |
| 12:45 ET | 446 | 13.655 |
| 12:48 ET | 500 | 13.63 |
| 12:52 ET | 500 | 13.6599 |
| 12:54 ET | 128 | 13.635 |
| 12:56 ET | 400 | 13.605 |
| 12:57 ET | 6443 | 13.51 |
| 12:59 ET | 869 | 13.53 |
| 01:01 ET | 332 | 13.53 |
| 01:03 ET | 2637 | 13.56 |
| 01:06 ET | 500 | 13.565 |
| 01:10 ET | 600 | 13.56 |
| 01:12 ET | 829 | 13.56 |
| 01:14 ET | 320 | 13.53 |
| 01:15 ET | 300 | 13.54 |
| 01:17 ET | 300 | 13.5381 |
| 01:19 ET | 4864 | 13.525 |
| 01:26 ET | 3500 | 13.55 |
| 01:28 ET | 2500 | 13.565 |
| 01:30 ET | 17416 | 13.43 |
| 01:33 ET | 500 | 13.4799 |
| 01:35 ET | 1216 | 13.44 |
| 01:37 ET | 500 | 13.5 |
| 01:39 ET | 1300 | 13.485 |
| 01:44 ET | 422 | 13.52 |
| 01:46 ET | 100 | 13.49 |
| 01:48 ET | 464 | 13.49 |
| 01:50 ET | 100 | 13.48 |
| 01:51 ET | 100 | 13.48 |
| 01:53 ET | 419 | 13.485 |
| 01:55 ET | 350 | 13.485 |
| 01:57 ET | 424 | 13.49 |
| 02:00 ET | 314 | 13.46 |
| 02:02 ET | 203 | 13.465 |
| 02:04 ET | 1093 | 13.48 |
| 02:11 ET | 507 | 13.495 |
| 02:13 ET | 2530 | 13.54 |
| 02:15 ET | 100 | 13.53 |
| 02:18 ET | 966 | 13.535 |
| 02:20 ET | 100 | 13.51 |
| 02:22 ET | 100 | 13.52 |
| 02:24 ET | 3316 | 13.525 |
| 02:26 ET | 764 | 13.51 |
| 02:27 ET | 460 | 13.49 |
| 02:29 ET | 2400 | 13.475 |
| 02:31 ET | 1980 | 13.48 |
| 02:33 ET | 215 | 13.49 |
| 02:36 ET | 400 | 13.49 |
| 02:40 ET | 1000 | 13.495 |
| 02:42 ET | 1766 | 13.495 |
| 02:44 ET | 609 | 13.495 |
| 02:45 ET | 2930 | 13.475 |
| 02:47 ET | 1100 | 13.475 |
| 02:49 ET | 3321 | 13.52 |
| 02:51 ET | 1300 | 13.48 |
| 02:54 ET | 400 | 13.47 |
| 02:58 ET | 965 | 13.44 |
| 03:00 ET | 1748 | 13.475 |
| 03:02 ET | 400 | 13.475 |
| 03:03 ET | 1200 | 13.475 |
| 03:05 ET | 200 | 13.47 |
| 03:09 ET | 200 | 13.465 |
| 03:12 ET | 2157 | 13.5 |
| 03:14 ET | 518 | 13.5 |
| 03:16 ET | 314 | 13.5 |
| 03:18 ET | 300 | 13.505 |
| 03:20 ET | 2408 | 13.49 |
| 03:21 ET | 200 | 13.49 |
| 03:23 ET | 200 | 13.5 |
| 03:25 ET | 124 | 13.5 |
| 03:27 ET | 700 | 13.49 |
| 03:30 ET | 1571 | 13.475 |
| 03:32 ET | 1201 | 13.495 |
| 03:34 ET | 524 | 13.499 |
| 03:36 ET | 665 | 13.475 |
| 03:38 ET | 1809 | 13.48 |
| 03:39 ET | 2115 | 13.465 |
| 03:41 ET | 2930 | 13.48 |
| 03:43 ET | 2033 | 13.47 |
| 03:45 ET | 1839 | 13.46 |
| 03:48 ET | 3875 | 13.569 |
| 03:50 ET | 2088 | 13.56 |
| 03:52 ET | 4294 | 13.62 |
| 03:54 ET | 2572 | 13.64 |
| 03:56 ET | 3681 | 13.565 |
| 03:57 ET | 6257 | 13.555 |
| 03:59 ET | 121372 | 13.58 |
Jun 7, 2024
DJ REGENXBIO Initiated at Buy by Goldman Sachs, from 7:38AM ET on Friday Jun 07, 2024 by Dow Jones
7:38AM ET on Friday Jun 07, 2024 by Dow Jones
Jun 5, 2024
REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference, from 7:05AM ET on Wednesday Jun 05, 2024 by Dow Jones
7:05AM ET on Wednesday Jun 05, 2024 by Dow Jones
May 15, 2024
DJ REGENXBIO Is Maintained at Buy by HC Wainwright & Co., from 11:41AM ET on Wednesday May 15, 2024 by Dow Jones
11:41AM ET on Wednesday May 15, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Regenxbio Inc | 693.5M | -2.3x | --- |
SAGE Therapeutics Inc | 636.7M | -1.3x | --- |
Zymeworks Inc | 641.3M | -5.4x | --- |
WAVE Life Sciences Ltd | 711.5M | -12.0x | --- |
Y-mAbs Therapeutics Inc | 525.7M | -24.2x | --- |
Urogen Pharma Ltd | 477.3M | -3.9x | --- |
Company Information
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Contact Information
- Headquarters
- 9804 Medical Center DriveROCKVILLE, MD, United States 20850
- Phone
- 240-552-8181
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Allan Fox
- President, Chief Executive Officer, Director
- Kenneth Mills
- Chief Financial Officer, Executive Vice President
- Vittal Vasista
- Chief Operating Officer, Executive Vice President
- Curran Simpson
- Executive Vice President, Chief Scientific Officer
- Olivier Danos
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $693.5M |
|---|---|
Revenue (TTM) | $86.7M |
Shares Outstanding | 49.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.29 |
EPS | $-5.88 |
Book Value | $7.08 |
P/E Ratio | -2.3x |
Price/Sales (TTM) | 8.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -306.52% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
